Itzhak  Goldberg net worth and biography

Itzhak Goldberg Biography and Net Worth

Insider of Angion Biomedica
Dr Goldberg founded Angion in 1998 and served as Chairman of the Board, President, and CEO from 1998-2018. Prior to Angion, Dr. Goldberg was a faculty member at Harvard Medical School, Boston, MA, Radiation Oncologist-in-Chief for the North Shore-LIJ (Northwell) Health System, NY, and Professor at the Albert Einstein College of Medicine, Bronx, NY. Dr. Goldberg has made seminal contributions in the field of tyrosine kinase receptors and hepatocyte growth factor research and has been the driving force within Angion since he started the company. Under Dr. Goldberg’s leadership, Angion received continuous non-dilutive NIH, DOD, and NSF grants and successfully raised Series A/B funding.

How do I contact Itzhak Goldberg?

The corporate mailing address for Dr. Goldberg and other Angion Biomedica executives is 51 Charles Lindbergh Boulevard, Uniondale NY, 11553. Angion Biomedica can also be reached via phone at 415-655-4899 and via email at [email protected]. Learn More on Itzhak Goldberg's contact information.

Has Itzhak Goldberg been buying or selling shares of Angion Biomedica?

Itzhak Goldberg has not been actively trading shares of Angion Biomedica during the past quarter. Most recently, Itzhak Goldberg sold 3,211 shares of the business's stock in a transaction on Monday, December 6th. The shares were sold at an average price of $33.50, for a transaction totalling $107,568.50. Learn More on Itzhak Goldberg's trading history.

Who are Angion Biomedica's active insiders?

Angion Biomedica's insider roster includes Itzhak Goldberg (Insider), John Neylan (Insider), Jennifer Rhodes (Insider), and Jay Venkatesan (Insider). Learn More on Angion Biomedica's active insiders.

Itzhak Goldberg Insider Trading History at Angion Biomedica

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/6/2021Sell3,211$33.50$107,568.50View SEC Filing Icon  
12/3/2021Sell4,021$33.90$136,311.90View SEC Filing Icon  
12/1/2021Sell3,886$35.40$137,564.40View SEC Filing Icon  
See Full Table

Itzhak Goldberg Buying and Selling Activity at Angion Biomedica

This chart shows Itzhak Goldberg's buying and selling at Angion Biomedica by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Angion Biomedica Company Overview

Angion Biomedica logo
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $6.48
Low: $1.00
High: $10.00

2 Week Range

Now: N/A

Volume

224,800 shs

Average Volume

86,718 shs

Market Capitalization

$30.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6